AnnexonÂ Inc (ANNX)

Name: AnnexonÂ Inc (ANNX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: AnnexonÂ Inc (ANNX)

Stock Card

$5.02

$-0.24 (-4.48%)

As on 28-Aug-2026 13:37EDT

Market cap

$961 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

5.3

Div. Yield

0 %

AnnexonÂ Inc (ANNX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.97 High: 5.21

52 Week Range

Low: 2.03 High: 7.18

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.1 %
ROCE

-- %
Industry P/E

37.31
EV/EBITDA

-2.5
Debt to Equity

0
Book Value

$--
EPS

$-1.2
Face value

--
Shares outstanding

189,579,134

7 Years Aggregate

CFO

$-461.46 Mln

EBITDA

$-526.01 Mln

Net Profit

$-537.26 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
AnnexonÂ Inc (ANNX)	-0.1	-2.2	-7.0	137.7	21.6	-21.2	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
AnnexonÂ Inc (ANNX)	-2.1	12.9	-12.2	-55.0	-54.1
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
AnnexonÂ Inc (ANNX)	5.0	961.2	0.0	-202.7	--	-101.9	--	5.3
Amneal Pharmaceuticals Inc Class A (AMRX)	17.6	6,238.0	3,117.6	157.4	14.7	--	37.3	188.9
Axsome Therapeutics (AXSM)	200.5	10,883.2	776.6	-191.6	-17.6	-223.4	--	130.9
BridgeBio Pharma (BBIO)	77.1	15,932.7	691.8	-696.2	-89.1	--	--	123.7
Corcept Therapeutics (CORT)	113.8	13,215.0	830.8	54.9	3.2	8.1	271.7	18.7
Elanco Animal Health (ELAN)	24.1	11,971.8	5,020.0	-199.0	1.6	-3	--	1.8
Grifols S.A. - ADR	7.8	5,444.6	7,430.4	452.5	17.6	7	10.4	0.8
Ligand Pharmaceuticals (LGND)	279.9	5,707.4	290.5	197.2	82.5	19.9	29.6	5.9
Liquidia Technologies Inc (LQDA)	68.5	6,142.1	450.9	138.6	39.1	115.6	49	31.5
Twist Bioscience Corp (TWST)	141.4	9,129.6	431.8	-136.7	-30.8	-30.3	--	20.5

Shareholding Pattern

View Details

About AnnexonÂ Inc (ANNX)

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3... clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Read more

CEO, President & Director

Mr. Douglas Love Esq., J.D.
CEO, President & Director

Mr. Douglas Love Esq., J.D.
Headquarters

Brisbane, CA
Website

https://www.annexonbio.com

FAQs for AnnexonÂ Inc (ANNX)

What is the current share price of AnnexonÂ Inc (ANNX) Today?

The share price of AnnexonÂ Inc (ANNX) is $5.02 (NASDAQ) as of 28-Aug-2026 13:37 EDT. AnnexonÂ Inc (ANNX) has given a return of 21.59% in the last 3 years.

What is the current PB & PE ratio of AnnexonÂ Inc (ANNX)?

Since, TTM earnings of AnnexonÂ Inc (ANNX) is negative, P/E ratio is not available.
The P/B ratio of AnnexonÂ Inc (ANNX) is 5.26 times as on 21-Aug-2026, a 32 discount to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.